Maze Therapeutics (MAZE) Financials

Balance sheets

Sep 1, 2024Jun 1, 2024Dec 1, 2023Sep 1, 2023

Total Assets

$192.5 M(-10.8%)$215.8 M(+201.8%)$71.5 M-

Current Assets

$154.0 M(-14.2%)$179.4 M(+425.9%)$34.1 M-

Non Current Assets

$38.5 M(+5.8%)$36.4 M(-2.7%)$37.4 M-

Total Liabilities

$477.0 M(-0.2%)$478.2 M(+7.4%)$445.4 M-

Current Liabilities

$17.6 M(-18.8%)$21.6 M(+32.4%)$16.3 M-

Long Term Liabilities

$459.5 M(+0.6%)$456.6 M(+6.4%)$429.0 M-

Shareholders Equity

-$284.5 M(-8.4%)-$262.4 M(+29.8%)-$373.8 M-

Book Value

-$284.5 M(-8.4%)-$262.4 M(+29.8%)-$373.8 M-

Working Capital

$136.4 M(-13.6%)$157.8 M(+786.8%)$17.8 M-

Cash And Cash Equivalents

$149.6 M(-14.5%)$175.1 M(+500.4%)$29.2 M-

Accounts Payable

$1.0 M(-53.4%)$2.2 M(+8.1%)$2.0 M-

Accounts Receivable

----

Short Term Debt

$4.6 M(+1.0%)$4.6 M(+1.9%)$4.5 M-

Long Term Debt

$74.5 M(+2.6%)$72.7 M(+61.0%)$45.1 M-

Total Debt

$79.2 M(+2.5%)$77.2 M(+55.6%)$49.6 M(+100.0%)$0.0

Debt To Equity

-0.2(+37.9%)-0.3(-123.1%)-0.1-

Current Ratio

8.8(+5.7%)8.3(+297.1%)2.1-

Quick Ratio

----

Inventory

----

Retained Earnings

-$313.9 M(-8.6%)-$289.1 M(+26.9%)-$395.7 M-

PB Ratio

----

Income statements

Sep 1, 2024Jun 1, 2024Dec 1, 2023Sep 1, 2023

EPS

-$0.1--$0.1(-7.4%)-$0.1

TTM EPS

-$0.1--$0.2(-107.4%)-$0.1

Revenue

$2.5 M---

TTM Revenue

$2.5 M---

Total Expenses

$26.7 M-$23.1 M(-8.6%)$25.2 M

Operating Expenses

$26.7 M-$23.1 M(-8.6%)$25.2 M

Cost Of Goods Sold

----

TTM Cost Of Goods Sold

----

Gross Profit

----

TTM Gross Profit

----

Gross Margin

----

Operating Profit

-$24.2 M--$23.1 M(+8.6%)-$25.2 M

TTM Operating Profit

-$47.3 M--$48.3 M(-91.4%)-$25.2 M

Operating Margin

-969.2%---

Net Income

-$24.8 M--$26.6 M(-7.4%)-$24.7 M

TTM Net Income

-$51.3 M--$51.3 M(-107.4%)-$24.7 M

Net Margin

-990.1%---

EBIT

-$24.2 M--$23.1 M(+8.6%)-$25.2 M

TTM EBIT

-$47.3 M--$48.3 M(-91.4%)-$25.2 M

EBITDA

-$23.4 M--$22.1 M(+8.9%)-$24.2 M

TTM EBITDA

-$45.5 M--$46.3 M(-91.1%)-$24.2 M

Selling, General & Administrative Expenses

$6.9 M-$7.0 M(+21.4%)$5.8 M

TTM SGA

$13.9 M-$12.8 M(+121.4%)$5.8 M

Depreciation And Amortization

$2.6 M--$3.1 M

TTM D&A

$2.6 M--$3.1 M

Interest Expense

----

TTM Interest Expense

----

Income Tax

-$279.0 K--$0.0

TTM Income Tax

-$279.0 K--$0.0

PE Ratio

----

PS Ratio

----

Cashflow statements

Sep 1, 2024Jun 1, 2024Dec 1, 2023Sep 1, 2023

Cash From Operations

$98.4 M---$66.2 M

TTM CFO

$98.4 M---$66.2 M

Cash From Investing

-$542.0 K---$407.0 K

TTM CFI

-$542.0 K---$407.0 K

Cash From Financing

$22.6 M--$197.0 K

TTM CFF

$22.6 M--$197.0 K

Free Cash Flow

$97.9 M---$66.6 M

TTM FCF

$97.9 M---$66.6 M

CAPEX

$542.0 K---

TTM CAPEX

$542.0 K---

Dividends Paid

----

TTM Dividends Paid

----

TTM Dividend Per Share

----

TTM Dividend Yield

----

Payout Ratio

----